131 related articles for article (PubMed ID: 10194819)
1. The first combined vaccine against hepatitis A and B: an overview.
Thoelen S; Van Damme P; Leentvaar-Kuypers A; Leroux-Roels G; Bruguera M; Frei PC; Bakasenas V; Safary A
Vaccine; 1999 Mar; 17(13-14):1657-62. PubMed ID: 10194819
[TBL] [Abstract][Full Text] [Related]
2. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
[TBL] [Abstract][Full Text] [Related]
3. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study.
Burgess MA; Rodger AJ; Waite SA; Collard F
Vaccine; 2001 Sep; 19(32):4835-41. PubMed ID: 11535336
[TBL] [Abstract][Full Text] [Related]
4. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults.
Van Herck K; Leroux-Roels G; Van Damme P; Srinivasa K; Hoet B
Travel Med Infect Dis; 2007 May; 5(3):171-5. PubMed ID: 17448944
[TBL] [Abstract][Full Text] [Related]
5. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.
Van Herck K; Van Damme P; Collard F; Thoelen S
Scand J Gastroenterol; 1999 Dec; 34(12):1236-40. PubMed ID: 10636072
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children.
Guptan RC; Thakur V; Safary A; Sarin SK
Vaccine; 2002 May; 20(16):2102-6. PubMed ID: 11972979
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the reactogenicity and immunogenicity of a two injection combined high-dose hepatitis A and hepatitis B vaccine to those of Twinrix.
Greub G; Genton B; Safary A; Thoelen S; Frei PC
Vaccine; 2000 Dec; 19(9-10):1113-7. PubMed ID: 11137246
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults.
Bruguera M; Bayas JM; Vilella A; Tural C; González A; Vidal J; Dal-Ré R; Salleras L
Vaccine; 1996 Oct; 14(15):1407-11. PubMed ID: 8994314
[TBL] [Abstract][Full Text] [Related]
9. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
[TBL] [Abstract][Full Text] [Related]
10. A two dose combined hepatitis A and B vaccine in Chinese youngsters.
Lee SD; Chan CY; Yu MI; Wang YJ; Chang FY; Lo KJ; Safary A
J Med Virol; 1999 Sep; 59(1):1-4. PubMed ID: 10440800
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in healthy Chilean subjects.
Prado V; Riedemann S; Ibarra H; Potin M
Int J Infect Dis; 2002 Jun; 6(2):129-33. PubMed ID: 12121601
[TBL] [Abstract][Full Text] [Related]
12. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.
Van Damme P; Leroux-Roels G; Suryakiran P; Folschweiller N; Van Der Meeren O
Hum Vaccin Immunother; 2017 May; 13(5):972-980. PubMed ID: 28281907
[TBL] [Abstract][Full Text] [Related]
13. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults.
Knöll A; Hottenträger B; Kainz J; Bretschneider B; Jilg W
Vaccine; 2000 Apr; 18(19):2029-32. PubMed ID: 10706965
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
Maiwald H; Jilg W; Bock HL; Löscher T; Sonnenburg F
Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
[TBL] [Abstract][Full Text] [Related]
16. A new accelerated vaccination schedule for rapid protection against hepatitis A and B.
Nothdurft HD; Dietrich M; Zuckerman JN; Knobloch J; Kern P; Vollmar J; Sänger R
Vaccine; 2002 Jan; 20(7-8):1157-62. PubMed ID: 11803077
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
18. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of Twinrix in older adults: a critical analysis.
Stoffel M; Lievens M; Dieussaert I; Martin I; André F
Expert Rev Vaccines; 2003 Feb; 2(1):9-14. PubMed ID: 12901592
[TBL] [Abstract][Full Text] [Related]
20. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
